<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549143</url>
  </required_header>
  <id_info>
    <org_study_id>EPIDI060</org_study_id>
    <nct_id>NCT03549143</nct_id>
  </id_info>
  <brief_title>Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation</brief_title>
  <acronym>ROMERUS</acronym>
  <official_title>Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian
      Federation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Awareness about the disease in Russia is extremely low both among doctors and especially
      among patients. To date there are no data on the prevalence of the disease in Russia. This is
      the first study to show patient profile, main trigger factors and concomitant diseases among
      patients with Irritable Bowel Syndrome (IBS) in Russia. Also treatment characteristics for
      these patients in Russia will be measured. This study fills a lack of scientific data about
      prevalence of IBS and additional information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 25, 2017</start_date>
  <completion_date type="Actual">April 19, 2019</completion_date>
  <primary_completion_date type="Actual">April 19, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by sex</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by education</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by region of living</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by marriage status</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by type of IBS</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Findings of routine examination</measure>
    <time_frame>6 months</time_frame>
    <description>proportion of patients with confirmed IBS by routine examination among all patients met Rome IV criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidity</measure>
    <time_frame>Baseline</time_frame>
    <description>Proportion of patients with different diagnosis registered at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine treatment regimens</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Proportion of patients received each treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute score of the IBS symptoms measured by IBS-QoL scale</measure>
    <time_frame>Baseline, 1, 2, 4, and 6 months</time_frame>
    <description>Irritable Bowel Syndrome - Quality Of Life (IBS-QOL) questionnaire contains 34 questions assessed from 1 point = &quot;not at all&quot; till 5 point = &quot;a great deal&quot;. The sum of all items is used to calculate the total score. All items are negative framed with the greatest response scale equaling the worst QoL. Scores for all items are transformed to a 0 to 100 scale, ranging from 0 (worst QoL) to 100 (best QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of the IBS symptoms measured by IBS-QoL scale</measure>
    <time_frame>Baseline, 1, 2, 4, and 6 months</time_frame>
    <description>Irritable Bowel Syndrome - Quality Of Life (IBS-QOL) questionnaire contains 34 questions assessed from 1 point = &quot;not at all&quot; till 5 point = &quot;a great deal&quot;. The sum of all items is used to calculate the total score. All items are negative framed with the greatest response scale equaling the worst QoL. Scores for all items are transformed to a 0 to 100 scale, ranging from 0 (worst QoL) to 100 (best QoL). Positive change corresponds to better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesment by Global Patient Assessment scale</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
    <description>Global Patient Assessment contains one question to rate up patient's general complaints of GI-discomfort. A 5-point Likert scale is used as follow: `symptom-free, markedly improved, slightly improved, unchanged, worse`.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesment by Physician Global Assessment scale</measure>
    <time_frame>1 and 6 months</time_frame>
    <description>Physician Global Assessment contains one question to rate up patient's general complaints of GI-discomfort. A 5-point Likert scale is used as follow: `symptom-free, markedly improved, slightly improved, unchanged, worse`.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The national questionnaire of treatment compliance contains 5 questions with 4 answers each. The sum of all items is used to calculate the total score. The total score has the range from 0 (worst compliance) to 15 (best compliance).</description>
  </secondary_outcome>
  <enrollment type="Actual">1000</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IBS</intervention_name>
    <description>No intervention, description of routine practice only</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult subjects, male and female, aged from 18 up to 50 years with symptoms potentially
        indicative of IBS according to ROME IV criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18-50 y.o

          -  Patients suffering from Irritable bowel syndrome (abdominal pain and changes in bowel
             habit) as defined by Rome IV criteria and the absence of any relevant structural
             disease

          -  Patient's written authorization to provide data for the program

          -  Patients who are able to input him/herself data into patients' part of Electronic Data
             Capture (EDC)

        Exclusion Criteria:

        Presence of alarm features:

          -  positive family history of colorectal cancer, inflammatory bowel disease, celiac
             disease

          -  rectal bleeding in the absence of documented bleeding hemorrhoids or anal fissures

          -  unintentional weight loss

          -  severe anemia (according to local laboratory reference values)

          -  Fever (&gt; 37,5 degree Celsius)

          -  Night symptoms appearance

        Other:

          -  Significant and progressive change in: enlargement of the liver, spleen, lymph nodes;
             ascites; palpable mass in the abdomen / pelvic

          -  Pregnancy or lactation or the inability to use adequate contraception during the
             study;

          -  Other conditions that made the patients participation impossible (by investigator
             judgment)

          -  Previous enrollment in any other clinical study during the course of this study,
             including participation in a study within 30 days prior to informed consent.

          -  Prescribed by Health Care Professional(s) (HCP) and being currently treated or having
             been treated with spasmolytics within the 3 months prior to entering the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City Clinical Hospital #8</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Railway Clinical Hospital</name>
      <address>
        <city>Irkutsk</city>
        <zip>664005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #4</name>
      <address>
        <city>Ivanovo</city>
        <zip>153005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Republican Clinical Hospital of MoH UR</name>
      <address>
        <city>Izhevsk</city>
        <zip>426039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interregional Clinical Diagnostic Center</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Dobryj Doctor&quot;</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Branch Hospital AT ST. Krasnodar JSC &quot;RZD&quot;</name>
      <address>
        <city>Krasnodar</city>
        <zip>350072</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical ON Group Lyubertsy</name>
      <address>
        <city>Lyubertsy</city>
        <zip>140002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Health</name>
      <address>
        <city>Lyubertsy</city>
        <zip>140013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SM-Clinic</name>
      <address>
        <city>Lyubertsy</city>
        <zip>140013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multidisciplinary Medical Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of gastroenterology</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center 'Golden Orchid'</name>
      <address>
        <city>Moscow</city>
        <zip>111675</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Dpt of City Clinical Hospital #85</name>
      <address>
        <city>Moscow</city>
        <zip>115409</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blokhin Oncology Center</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9 MDC Ministry of Defense</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center on Timur Frunze Street</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDSI Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>123056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CP Litfonda</name>
      <address>
        <city>Moscow</city>
        <zip>125319</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamed Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>125368</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Larmed</name>
      <address>
        <city>Moscow</city>
        <zip>125475</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic 'Medic City'</name>
      <address>
        <city>Moscow</city>
        <zip>127220</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MSMSU them. A. I. Evdokimov</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPM LLC</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Multidisciplinary Medical Center ALTAME+</name>
      <address>
        <city>Odintsovo</city>
        <zip>143006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Industrial Medicine Clinic, polyclinic No1</name>
      <address>
        <city>Orenburg</city>
        <zip>46000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treatment and Rehabilitation Center No1</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi Com LLC (SM-clinic)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195279</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC 'Avesta MDC-M'</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Clinical Diagnostic Center</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OKD Diagnostic Center</name>
      <address>
        <city>Surgut</city>
        <zip>628415</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulvative and Diagnostic Center Endos</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuvatov RCH</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamed Llc</name>
      <address>
        <city>Vladivostok</city>
        <zip>690087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Medic LLC</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Chance LLC</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Medical Center&quot; Doctor Plus</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>6220018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS; Irritable Bowel Syndrome; spasmolytics; mebeverine; Duspatalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 25, 2020</submitted>
    <returned>July 14, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

